ArticleCancers2022
Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- A Phase 2 Study of Tislelizumab as Neoadjuvant Treatment of Cisplatin-Ineligible High-Risk Upper Tract Urothelial Carcinoma.The Journal of urology · 2025Trial
- Reproducibility and diagnostic performance of ADC for assessing response to neoadjuvant immunotherapy in muscle-invasive bladder cancer: a multi-ROI comparison analysis from the phase-Ib NABUCCO trial.Insights into imaging · 2026Article
- Temporal lymph node imaging features for prognostic risk stratification in neoadjuvant immunotherapy for esophageal cancer: a multicenter study.European radiology · 2026Article
- Image Quality Assessment of Diffusion-Weighted Imaging (DWI) and Its Impact on Apparent Diffusion Coefficient (ADC) as a Quantitative Imaging Biomarker for Predicting Response to Neoadjuvant Chemotherapy in High-Risk Early Breast Cancer.Tomography (Ann Arbor, Mich.) · 2026Article
- Development and multicenter validation of an immunoinflammatory marker-MRI model for pathological complete response after neoadjuvant chemotherapy in invasive breast cancer.Translational cancer research · 2026Article
- Early Tumor Shrinkage and Depth of Response as Predictive Markers of Treatment Response and Prognosis in Solid Tumors.Cancer medicine · 2025Review
- Evaluating Breast Cancer Intravoxel Incoherent Motion MRI Biomarkers across Software Platforms.Radiology. Imaging cancer · 2025Article
- The value of diffusion-weighted imaging and semi-quantitative dynamic contrast-enhanced MRI in predicting the efficacy of medroxyprogesterone acetate treatment for atypical endometrial hyperplasia and endometrial carcinoma.BMC medical imaging · 2025Article
- Discrimination Between Benign and Malignant Lesions With Restriction Spectrum Imaging MRI in an Enriched Breast Cancer Screening Cohort.Journal of magnetic resonance imaging : JMRI · 2025Article
- Article
- Non-contrast Breast MR Imaging.Radiologic clinics of North America · 2024Review
- Multiparametric MRI for characterization of the tumour microenvironment.Nature reviews. Clinical oncology · 2024Review
- Integrating Imaging and Circulating Tumor DNA Features for Predicting Patient Outcomes.Cancers · 2024Review
- Magnetic resonance imaging-based approaches for detecting the efficacy of combining therapy following VEGFR-2 and PD-1 blockade in a colon cancer model.Journal of translational medicine · 2024Article
- The development process of 'fit-for-purpose' imaging biomarkers to characterize the tumor microenvironment.Frontiers in medicine · 2024Review
- Development and Assessment of a Novel Core Biopsy-Based Prediction Model for Pathological Complete Response to Neoadjuvant Chemotherapy in Women with Breast Cancer.International journal of environmental research and public health · 2023Article
- Skin Cancer Pathobiology at a Glance: A Focus on Imaging Techniques and Their Potential for Improved Diagnosis and Surveillance in Clinical Cohorts.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
This study tested the hypothesis that a change in the apparent diffusion coefficient (ADC) measured in diffusion-weighted MRI (DWI) is an independent imaging marker, and ADC performs better than functional tumor volume (FTV) for assessing treatment response in patients with locally advanced breast cancer receiving neoadjuvant immunotherapy. A total of 249 patients were randomized to standard neoadjuvant chemotherapy with pembrolizumab (pembro) or without pembrolizumab (control). DCE-MRI and DWI, performed prior to and 3 weeks after the start of treatment, were analyzed. Percent changes of tumor ADC metrics (mean, 5th to 95th percentiles of ADC histogram) and FTV were evaluated for the prediction of pathologic complete response (pCR) using a logistic regression model. The area under the ROC curve (AUC) estimated for the percent change in mean ADC was higher in the pembro cohort (0.73, 95% confidence interval [CI]: 0.52 to 0.93) than in the control cohort (0.63, 95% CI: 0.43 to 0.83). In the control cohort, the percent change of the 95th percentile ADC achieved the highest AUC, 0.69 (95% CI: 0.52 to 0.85). In the pembro cohort, the percent change of the 25th percentile ADC achieved the highest AUC, 0.75 (95% CI: 0.55 to 0.95). AUCs estimated for percent change of FTV were 0.61 (95% CI: 0.39 to 0.83) and 0.66 (95% CI: 0.47 to 0.85) for the pembro and control cohorts, respectively. Tumor ADC may perform better than FTV to predict pCR at an early treatment time-point during neoadjuvant immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.